187 related articles for article (PubMed ID: 22864732)
21. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers.
Jeon H; Lim KS; Shin KH; Kim J; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2012 Jan; 59(1):84-91. PubMed ID: 21934629
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients.
Scholze J; Schaefer A; Kreutz R
Expert Opin Drug Saf; 2011 Mar; 10(2):185-96. PubMed ID: 21254872
[TBL] [Abstract][Full Text] [Related]
23. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives.
Angeli F; Verdecchia P; Trapasso M; Pane M; Signorotti S; Reboldi G
Expert Opin Drug Metab Toxicol; 2018 May; 14(5):533-541. PubMed ID: 29676941
[TBL] [Abstract][Full Text] [Related]
24. A look through the new therapeutic window: irbesartan.
Waeber B; Brunner HR
J Hypertens Suppl; 1998 Sep; 16(7):S11-6. PubMed ID: 9855026
[TBL] [Abstract][Full Text] [Related]
25. A new class of antihypertensive therapy: angiotensin II receptor antagonists.
Ellis ML; Patterson JH
Pharmacotherapy; 1996; 16(5):849-60. PubMed ID: 8888079
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of high-normal blood pressure with angiotensin receptor blockers. TROPHY Study (Trial of Preventing Hypertension)].
Mann J
Internist (Berl); 2007 Apr; 48(4):436-8. PubMed ID: 17342351
[No Abstract] [Full Text] [Related]
27. Hypertension after kidney transplantation: still a SECRET?
Lopau K; Wanner C
Nephrol Dial Transplant; 2010 Mar; 25(3):664-5. PubMed ID: 20042402
[No Abstract] [Full Text] [Related]
28. Losartan for hypertension.
Med Lett Drugs Ther; 1995 Jun; 37(951):57-8. PubMed ID: 7783693
[No Abstract] [Full Text] [Related]
29. Angiotensin II receptors and angiotensin II receptor antagonists.
Timmermans PB; Wong PC; Chiu AT; Herblin WF; Benfield P; Carini DJ; Lee RJ; Wexler RR; Saye JA; Smith RD
Pharmacol Rev; 1993 Jun; 45(2):205-51. PubMed ID: 8372104
[No Abstract] [Full Text] [Related]
30. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers.
Kang WY; Kim EH; Seong SJ; Gwon MR; Yang DH; Kim HJ; Lim MS; Lee HW; Yoon YR
Int J Clin Pharmacol Ther; 2016 Dec; 54(12):992-1003. PubMed ID: 27668695
[TBL] [Abstract][Full Text] [Related]
32. [Angiotensin II receptor antagonists].
Bornkessel B
Med Monatsschr Pharm; 1995 Jun; 18(6):148-51. PubMed ID: 7609710
[No Abstract] [Full Text] [Related]
33. Irbesartan treatment in hypertension.
Brown MJ
Hosp Med; 1998 Oct; 59(10):808-11. PubMed ID: 9850301
[TBL] [Abstract][Full Text] [Related]
34. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
Dahlöf B
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
[TBL] [Abstract][Full Text] [Related]
35. Treating prehypertension.
Baumann M; van den Born BJ
N Engl J Med; 2006 Jul; 355(4):416-8; author reply. PubMed ID: 16874901
[No Abstract] [Full Text] [Related]
36. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
Mallion JM; Goldberg AI
Blood Press Suppl; 1996; 2():82-6. PubMed ID: 8913546
[TBL] [Abstract][Full Text] [Related]
37. Effect of age on the pharmacokinetics of fimasartan (BR-A-657).
Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Cho JY; Yu KS; Yoon YR
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1337-44. PubMed ID: 21950382
[TBL] [Abstract][Full Text] [Related]
38. [Antihypertensive drug therapy--combination of AT1-receptor blocker and betablocker].
Schindler C; Kosa M; Schröder J; Kirch W
Dtsch Med Wochenschr; 2010 May; 135(3):98. PubMed ID: 20077385
[No Abstract] [Full Text] [Related]
39. [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension].
Hagino T; Abe K; Tsunoda K; Yoshinaga K
Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):133-40. PubMed ID: 1588765
[TBL] [Abstract][Full Text] [Related]
40. Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan.
Choung W; Jung HJ; Nam EH; Yang D; Yoo B; Choi H; Lee BR; Park M; Jang SM; Lim JS; Kim KH; Chin J; Jung K; Lee G; Kim SH
Bioorg Med Chem Lett; 2018 Oct; 28(19):3155-3160. PubMed ID: 30177375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
